Evidence map›Paper›PMID 36551691›Full record

ArticleCancers2022

Coxsackievirus Group B3 Has Oncolytic Activity against Colon Cancer through Gasdermin E-Mediated Pyroptosis.

Yejia Zhang, Tian Xu, Huizhen Tian, Jianfeng Wu, Xiaomin Yu, Lingbing Zeng, Fadi Liu, Qiong Liu, Xiaotian Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yejia ZhangDepartment of Medical Microbiology, School of Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Tian XuDepartment of Medical Microbiology, School of Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Huizhen TianDepartment of Medical Microbiology, School of Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Jianfeng WuDepartment of Medical Microbiology, School of Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Xiaomin YuDepartment of Medical Microbiology, School of Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Lingbing ZengDepartment of Medical Microbiology, School of Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Fadi LiuThe Department of Clinical Laboratory, Children's Hospital of Jiangxi Province, Nanchang 330006, China.
Qiong LiuDepartment of Medical Microbiology, School of Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Xiaotian HuangDepartment of Medical Microbiology, School of Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Nanchang University · CNJiangxi Provincial Children's Hospital · CN

Funding

National Innovation and Entrepreneurship Training Program for college students 202110403093National Natural Science Foundation of China 32060040National Natural Science Foundation of China 32260193National Natural Science Foundation of China 82203032Natural Science Foundation of Jiangxi Province 20202BAB206062Training Plan for Academic and Technical Leaders of Major Disciplines in Jiangxi Province-Youth Talent Project 20212BCJ23036
6 · The paper itself

Abstract

Colon cancer is the second leading cause of cancer-related death, and there are few effective therapies for colon cancer. This study explored the use of coxsackievirus group B3 (CVB3) as an oncolytic virus for the treatment of colon cancer. In this study, we verified that CVB3 induces death of colon cancer cell lines by directly observing cell morphology and Western blot results, and observed the oncolytic effects of CVB3 by constructing an immunodeficient nude mice model. Our data show that CVB3 induces pyroptosis in colon cancer cell lines. Mechanistically, we demonstrated that CVB3 causes cleavage of gasdermin E (GSDME), but not gasdermin D (GSDMD), by activating caspase-3. This leads to production of GSDME N-termini and the development of pores in the plasma membrane, inducing pyroptosis of colon cancer cell lines. We also demonstrate that CVB3-induced pyroptosis is promoted by reactive oxygen species (ROS). Finally, in vivo studies using immunodeficient nude mice revealed that intratumoral injection of CVB3 led to significant tumor regression. Our findings indicate that CVB3 has oncolytic activity in colon cancer cell lines via GSDME-mediated pyroptosis.

Indexed as

caspase-3colon cancercoxsackievirus group B3GSDMEoncolytic virusespyroptosis

Identifiers

PMID36551691
PMCPMC9776948
OpenAlexW4311688128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.